All In Biotech

Free tool

FAERS Monitor: Riabni

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761140 or its brand name (Riabni, Rituximab-Arrx). Reports on generic versions are filed under their own applications.

Reports

384

Serious

63

16% of reports

Hospitalization

28

Death reported

14

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product storage error165
  • circumstance or information capable of leading to medication error116
  • off label use64
  • intercepted product administration error51
  • fatigue19
  • infusion related reaction18
  • accidental exposure to product17
  • drug ineffective16
  • dyspnoea16
  • intercepted product preparation error16
  • malaise15
  • pruritus15
  • dizziness14
  • drug intolerance14
  • rash13

Reports by year received

View as table
YearReports
20171
20181
20218
202249
2023121
2024143
202539
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,775 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intercepted product administration errorSignal51366.8283.818,125
circumstance or information capable of leading to medication errorSignal116188.8162.121,438
product storage errorSignal165103.492.216,673
intercepted product preparation errorSignal1671.344.11,039
infusion related reactionSignal1814.99.5220
accidental exposure to productSignal179.05.7114
drug intoleranceSignal147.94.778
off label useSignal644.03.2147
pruritusSignal152.11.38
malaise151.91.15
rash131.61.03
dyspnoea161.51.03
dizziness141.50.92
fatigue191.30.91
drug ineffective160.70.43

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.